SCHEMBL5178485

SCHEMBL5178485

N#CC1(c2ccc(CNC(=O)Cc3cccc(C(F)(F)F)c3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
BACE1 P56817 2/20 0.52
LMNA P02545 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 2/20 0.46
BACE2 Q9Y5Z0 1/20 0.46
SMYD3 Q9H7B4 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
POLB P06746 1/20 0.44
MAPK8 P45983 1/20 0.43
ERCC1 P07992 1/20 0.43
ERCC4 Q92889 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5176408 0.84 BACE1 (0.55) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL5175704 0.82 BACE1 (0.53) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL5176610 0.82 BACE1 (0.53) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL9849523 0.80 MEN1 (0.70) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL5178730 0.80 BACE1 (0.51) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL5176587 0.79 PARP1 (0.48) MEN1KMT2AHDAC1HDAC8CYP3A4
SCHEMBL3571475 0.77 BACE1 (0.60) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL3235987 0.77 BACE1 (0.60) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL3572811 0.77 BACE1 (0.60) NPC1RAB9ABACE1LMNAL3MBTL1
SCHEMBL3569054 0.77 BACE1 (0.57) NPC1RAB9ABACE1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259183-B2 Indole, indazole and indoline derivatives as CETP inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
EP-1776338-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-25 EP disclosed
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors F. HOFFMANN-LA ROCHE AG (CH) 2006-02-09 US disclosed
WO-2006013048-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030613-A1 Indole, indazole and indoline derivatives as CETP inhibitors CETP, NAT1, MTTP NPC1 6/4885RAB9A 3309/4885BACE1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.